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ABSTRACT
The purpose of this review is to comprehensively
examine the various therapeutic agents available
totreatautoimmuneeyedisease,theirindications,
clinical safety and recent developments. The
stepladder approach is reviewed, including
corticosteroid administration of various forms,
classic immunomodulators, and newer biologic
response modiﬁers. The authors present that
corticosteroid monotherapy is almost never
curative and carries signiﬁcant side effects, while
immunomodulatory therapy, when used
appropriately as way to induce steroid-free
remission, carries far less risk of causing long-
termcomplicationsandprovidesgreaterpotential
ofalteringtheimmunesystemtoinduceadurable
remission.
Keywords: Corticosteroid;
Immunomodulatory therapy; Inﬂammation;
Ophthalmology; Uveitis
INTRODUCTION
Uveitis is the third leading cause of preventable
blindness in the United States. Vision loss from
uveitis can be secondary to cystoid macular
edema, glaucoma, cataract, retinal vasculature
abnormalities, corneal opacities, optic nerve
atrophy, retinal and macular lesions. New
modalities and effective therapies to control
ocular inﬂammatory disease have been
developed. The goal of therapy is to suppress
the immune inﬂammatory response in order to
preserve the integrity of the eye and therefore
preserve visual function. The choice of agent is
based on the patient’s underlying disease, age,
sex, medical conditions, and risk factors. The
patient is monitored closely to assess the
response and to screen for adverse effects.
Therapy is continued with the mission to
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DOI 10.1007/s40123-014-0023-xachieve quiescence of inﬂammation for a period
of 2 years prior to considering tapering or
discontinuation. This review will focus on the
various therapeutic agents available to treat
autoimmune eye disease, its indications,
clinical safety and recent developments.
DISCUSSION
Corticosteroids
Corticosteroids therapy has been used
extensively in the treatment of non-infectious
uveitis. It can be administered in the form of
topical drops, intravitreal and periocular
injections, intravitreal implants and
systemically which will be described [1].
Corticosteroids (mineralocorticoids and
glucocorticoids) are naturally produced in
response to adrenocorticotropic hormone
(ACTH)-induced conversion of cholesterol to
pregnolone in the adrenal cortex.
Glucocorticoids regulate gluconeogenesis and
inhibit the inﬂammatory response. On the
other hand, mineralocorticoids regulate the
body’s ion balance by controlling inorganic
ion reabsorption by the kidney. Corticosteroids
are composed of 21 carbon molecules consisting
of three hexane rings, one pentane ring and
cyclopentanoperhydrophenanthrene nucleus
[2]. Changes in this basic structure gives rise to
different compounds with different biologic
properties such as anti-inﬂammatory activity,
duration of action, trans-corneal penetration,
sodium retaining activity, efﬁcacy and side
effect proﬁle [2].
The mechanism of corticosteroids has a
direct impact on protein synthesis at the
cellular level by switching gene transcription
on and off. Corticosteroid receptors have been
isolated in the ciliary body, corneoscleral tissue
and iris. Glucocorticoids inhibit vascular
permeability and vasodilation thereby
affecting leukocyte migration to sites of
inﬂammation and leukocyte distribution and
survival. In addition, the distribution and
maturation of lymphocytes in the thymus is
also affected leading to lymphocytopenia.
Long-term high doses may affect B
lymphocytes and antibody production while
small and moderate doses have an impact on T
lymphocytes [2]. The production of
neutrophils, as well as their adhesion to the
vascular endothelium and their migration to
sites of inﬂammation from the intravascular
space, is affected. There is a reduction of
circulating monocytes and eosinophils and a
decrease in macrophage recruitment and their
ability to act as antigen presenting cells.
Corticosteroids stabilize the membranes of
basophils and mast cells thereby inhibiting
degranulation and the release of inﬂammatory
mediators. Corticosteroids inhibit
phospholipase A2, thereby affecting the
conversion of phospholipid to arachidonic
acid. The end result is inhibition of
prostaglandin production through the
cyclooxygenase pathway and inhibition in
production of leukotrienes through the
lipooxygenase pathway [2].
Topical Corticosteroids
Topical corticosteroids are frequently employed
as the initial therapy for uveitis, speciﬁcally for
anterior uveitis. The drops can be easily
administered by the patient and frequency of
dosing can be modiﬁed and tapered based on
the degree of inﬂammation. There is wide
variety of topical steroids available in the
market with a range of anti-inﬂammatory
activity. The most commonly prescribed is
prednisolone acetate 1%, which is adequate
for most cases of uncomplicated anterior
18 Ophthalmol Ther (2014) 3:17–36uveitis. Less potent options include loteprednol
and rimexolone that can be used when there is a
concern about elevated intraocular pressure [3].
However, these agents may not be adequate for
severe anterior uveitis. Recent studies have
demonstrated the efﬁcacy of diﬂuprednate
ophthalmic solution 0.05% in the treatment
of anterior uveitis requiring less frequent
administration when compared to
prednisolone acetate 1% [4].
Topical steroid use should be monitored
closely and long-term use should be limited
since corticosteroids can cause cataract and
glaucoma. Topical steroids should be used
with caution in patients with a history of
intraocular infection and compromised
corneal surface to avoid recurrence or onset
of infectious processes such as herpetic
keratitis. Topical therapy should be
aggressive in the beginning with frequent
dosing in order to halt the inﬂammation
and then be tapered to avoid rebound
inﬂammation [1, 2].
Periocular Corticosteroid
In cases of intermediate and posterior uveitis
where topical therapy is not sufﬁcient, trans-
septal, sub-Tenon’s space or subconjunctival
injection can offer an alternative. The most
common agent used in these injections is
triamcinolone acetate. These injections offer
the beneﬁt of local therapy and extended effect,
whilst limiting systemic side effects. The patient
needs to demonstrate cooperation in order to
receive these injections. The drawbacks include
eliciting steroid response and close monitoring
of intraocular pressure. Patients should also be
counseled about possible orbital fat atrophy or
prolapse, ptosis or proptosis after repeated
injections that may alter their cosmetic
appearance.
Intravitreal Corticosteroids
Intraocular injections can be an alternativeif the
inﬂammation is unilateral, mild to moderate in
nature or in situations where it is recalcitrant to
periocular and systemic administration. The
effects can be transient with duration of about
3 months therefore requiring repeated
injections. Agents such as triamcinolone have
been employed with success and can be quite
useful in reducing macular edema and
improving visual acuity [2]. Water-soluble
steroids have a shorter duration and may not
be sufﬁcient in controlling cystoid macular
edema. The risks include frequent injections
that can increase the risk of endophthalmitis
and retinal detachment. The injections also
carry the same side effect proﬁle of elevated
intraocular pressure and cataracts [5].
Intravitreal Implants
In order to address the need for frequent
intraocular steroid administration, sustained-
release delivery vehicles have been developed
such as Retisert
 (Bausch ? Lomb, Bridgewater,
NJ,USA)andOzurdex
(Allergan,Irvine,CA,USA).
Retisert
 was approved in April 2005 in the
United States for the treatment of chronic, non-
infectious uveitis affecting the posterior
segment of the eye. It is a non-biodegradable
sustained delivery ﬂuocinolone acetonide
intravitreal implant that is surgically
implanted in the posterior segment [5].
It releases ﬂuocinolone acetonide, a
synthetic corticosteroid, 0.6 lg/day during
the ﬁrst month and then 0.3–0.4 lg/day at
a stable rate over the next 30 months.
Systemic absorption has been shown to be
minimal. Clinical studies have demonstrated
improvement of visual acuity of more than
three lines after 34 weeks of having the implant
placed in about 19–21% of patients. About
15–17% of Retisert recipients who noted an
Ophthalmol Ther (2014) 3:17–36 19improvement in vision at the 34-week mark
were able to maintain the improvement. The
Retisert implant has been shown to reduce
uveitis recurrences, improve visual acuity, and
decrease the need for adjunctive therapy [6].
Nevertheless, Retisert recipients have been
shown to develop cataracts and glaucoma
often necessitating additional cataract and
glaucoma ﬁltering surgery. In studies
comparing Retisert and standard systemic
therapy, there was an increased incidence of
cataracts and glaucoma where cataract
formation was noted in 88–93% in patients
with Retisert and 21–40% of patients required
glaucoma surgery [7, 8].
Ozurdex
 is Food and Drug Administration
(FDA) approved to treat adults with macular
edema after a branch or central retinal vein
occlusion or adults with non-infectious
posterior uveitis. It is a 0.7 mg dexamethasone
biodegradable drug delivery system that is
inserted into the vitreous in an outpatient
setting. The implant lasts about 3 months and
has been found to be effective with better side
effect proﬁle when compared with intravitreal
triamcinolone injections and Retisert. It was
originally approved in 2009 for the treatment of
macular edema. It offers an alternative for
patients who may need repeated intravitreal
injections, but are not yet ready to proceed with
surgical Retisert implantation.
In a study comparing Ozurdex and Retisert
implants, no eyes in the Ozurdex group needed
additional glaucoma medications, surgery or
laser, compared to 44% of eyes in the Retisert
group. Eyes with the Retisert implant had a
statistically higher rate of having more
glaucoma medications and surgery. With
regard to cataracts, in the Ozurdex group, 50%
of phakic eyes at baseline had cataract
progression and subsequent surgery compared
with 100% of Retisert phakic eyes. Eyes with the
Retisert implant were 4.7 times more at risk of
cataract progression [9].
Systemic Steroids
In the situation of refractory uveitis and the
need for immediate control, systemic steroids
can be employed in the oral or intravenous
route. High doses of oral steroids may be
necessary to quell the inﬂammation initially,
followed by a taper. The typical dose can be
1 mg/kg daily. If disease control requires more
than 10 mg of prednisone daily,
immunosuppressive therapy should be
discussed. The patient needs to be advised
about the importance of tapering the steroids
appropriately to avoid recurrence of
inﬂammation and an adrenal crisis. Patients
should also be aware that the hypothalamic-
pituitary axis may not return to baseline
6–12 months after chronic oral steroid therapy
has been discontinued [10].
Pulse intravenous steroids are used if
immediate control is required or if the patient
does not tolerate high doses of oral steroids. A
regimen of intravenous methylprednisolone
1 g/day for 3 days with transition to oral
steroids can be used. It should be administered
over a period of 30 min or longer [1, 10].
The side effect proﬁle is signiﬁcant with
notable mention of osteoporosis even with
doses as low as 7.5 mg per day. Prolonged
steroid use warrants close bone density
monitoring and bone preservation therapy. It
is important to counsel patients about possible
weight gain, mood changes, insomnia,
hyperglycemia, easy bruising, skin atrophy and
striae, and susceptibility to infection. Less
common, but more severe adverse effects
include aseptic bone necrosis, pancreatitis,
myopathy and psychosis. Patients on
corticosteroids and non-steroidal anti-
inﬂammatory should be monitored for the
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therapy should be started if they occur. Ocular
side effects also include cataract formation and
elevation of intraocular pressure [1, 10].
Immunomodulatory Drugs
Patients with chronic ocular inﬂammation often
beneﬁt from long-term management with
steroid-sparing therapy. Immunomodulators
can be considered in patients with systemic
disease affecting multiple organ systems such as
in the case of patient with sarcoidosis,
rheumatoid arthritis and juvenile idiopathic
arthritis (JIA) among others. Other scenarios
include steroid intolerance or cases of uveitis
such as Behcet’s disease, sympathetic
ophthalmia, Vogt–Koyanagi–Harada syndrome
and rheumatoid scleritis that warrants
immediate use of immunomodulators. Prior to
starting therapy the patients age, type and
severity of inﬂammation, associated medical
conditions and type of family planning must
be assessed carefully [2, 11].
In discussing immunomodulatory therapy
with patients, compliance with medication,
ofﬁce visits and laboratory testing, birth
control methods to be used while the patient
is taking immunomodulators and in-depth
counseling with regard to the medication side
effects and possible off-label use need to be
assessed. The need to receive killed vaccines
such as the inﬂuenza vaccines and never receive
live vaccines, the need to conduct baseline
laboratory testing such as complete blood
count (CBC), liver function tests (LFT), and
renal function tests and patient understanding
to stop immunomodulator therapy in the
setting of infection should also be assessed.
Finally, the patient should be made aware of the
teamwork approach with their primary care
doctor, pediatrician or rheumatologist.
Antimetabolites
Methotrexate
The pharmacology involves inhibition of DNA
replication by using a folate analog that
interferes with DNA synthesis. It reduces
cellular and humoral immune responses by
affecting proliferation, inducing T-cell
apoptosis, altering B-cell response, inhibiting
cytokine production and also with
antiangiogenic properties. The most common
indication for its use is a patient who is steroid
intolerant and needs more long-term
management such as in the case of chronic
uveitis or scleritis. The Systemic
Immunosuppressive Therapy for Eye Diseases
(SITE) multi-center retrospective cohort study of
384 patients treated with methotrexate as the
only immunosuppressant for ocular
inﬂammation showed that 66% of patients
were able to achieve quiescence of their ocular
inﬂammation within a year, also permitting a
taper of systemic steroids [5]. Methotrexate was
employed in controlling anterior uveitis,
posterior uveitis, panuveitis and mucous
membrane pemphigoid. Therapy success was
most commonly achieved in patients with
anterior uveitis and scleritis. Methotrexate has
a long track record and has been safely and
efﬁciently used in the adult as well as in the
pediatric population. It is available in the oral,
subcutaneous and intravenous administration.
It is provided in doses of 7.5 mg and up to
25 mg once a week. Folic acid (1 mg) daily is
also employed to limit side effects due to folate
deﬁciency. It takes about 3–6 weeks for
methotrexate to become effective. Side effects
may include bone marrow suppression, elevated
liver enzymes, fatigue, malaise, gastrointestinal
discomfort. These side effects are typically
reversible with dose reduction or by stopping
the medication. The subcutaneous route can be
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affecting its tolerability. Therapy is continued
for 2 years after quiescence is achieved to be
able to obtain durable remission. If no adequate
control is achieved, the dose can be increased by
5 mg per week. If no improvement is noted
another agent can be added or methotrexate
needs to be replaced. Important laboratory
testing to follow include complete blood
counts (CBC), liver enzymes (LFT) and
creatinine at 6-week intervals to assess for any
kind of toxicity [5].
Mycophenolate Mofetil
Mycophenolate mofetil (MMF) inhibits inosine
monophosphate dehydrogenase causing a
reduction of nucleotides required for purine
synthesis, DNA synthesis and for B- and T-cell
proliferation. It also interferes with cell
adhesion on vascular endothelium,
lymphocytic chemotaxis and decreases
antibody synthesis [5].
Mycophenolate has been successfully
employed as monotherapy or in conjunction
with steroids, cyclosporine, azathioprine and
methotrexate to treat ocular inﬂammation [12].
It can also be the next agent to be employed if a
patient does not tolerate methotrexate. In the
SITE cohort study which included 236 patients
with ocular inﬂammatory disease, 73% of them
were able to achieve inﬂammation control
within 1 year, while 55% of patients were able
to experience a steroid-sparing effect at the
1 year mark [13].
Side effects led to the discontinuation of
MMF in 12% of patients during the ﬁrst year.
The SITE study also showed no increase in
overall or cancer-related mortality in patients
who were treated with MMF when compared to
untreated controls [11, 14].
The starting dose of MMF is 500 mg twice a
day by oral routeon an empty stomach, 1 hprior
to eating or 2 h after meals while assessing for
side effects. If the patient is tolerating the
medication well, the dose can be increased to
1 gtwiceadaywithamaximumdoseof3 gaday.
The most common side effect is gastrointestinal
irritability, followed by bone marrow
suppression and elevated liver function tests.
Baseline laboratory testing such as CBC with
differential, liver function tests are done at the
onset of therapy and then monitored every
4–6 weeks. Duration of therapy is usually
2 yearsinordertoachievesteroid-freeremission.
Azathioprine
Azathioprine is a prodrug that it is metabolized
in the liver to the active form,
6-mercaptopurine, that is then converted to
thioinosine 5-phosphate, that serves as a purine
analog that interferes with RNA and DNA
synthesis [2]. It has been shown to inhibit
T-lymphocyte function, interferes with
targeting of circulating T cells, decreases the
development of monocyte precursors,
suppresses type IV hypersensitivity reaction,
and interferes with the participation of natural
killer (NK) cells in the antibody-dependent
cytotoxic reactions [11]. The SITE study
included 145 patients treated with
azathioprine for ocular inﬂammatory
conditions and 62% of these patients were
able to achieve quiescence of inﬂammation
and 47% were able to experience a steroid-
sparing effect. Inﬂammation control with
azathioprine was most commonly achieved in
patients with intermediate uveitis [11]. During a
median follow-up of 230 days, 24% of patients
stopped therapy due to side effects including
gastrointestinal discomfort, bone marrow
suppression, altered liver functions, infections
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patients achieved remission and were able to
stop therapy. The SITE study showed no
increased risk of mortality or cancer in
patients taking azathioprine when compared
to controls who never took the therapy [14, 15].
It is typically given at an initial dose of
2–3 mg/kg/day orally and the dose is then
adjusted based on clinical response and side
effect proﬁle. Baseline testing at the
beginning of therapy should include a CBC
with differential, LFT and quantitative testing
for thiopurine methyltransferase enzyme
activity. It should not be given to patients
who have low or absent enzyme activity. If a
patient is also taking allopurinol, the
azathioprine dose should be reduced by
25%. Follow-up CBC and liver function tests
should be done at 4- to 6-week intervals.
Therapy should be maintained typically for
2 years with the goal of durable steroid-free
remission.
Cyclosporine
Cyclosporine (CsA) is a fungal anti-metabolite
primarily used in solid organ transplantation. It
is postulated that CsA reversibly inhibits T-cell
mediated alloimmune and autoimmune
responses. Its mechanism of action is not fully
understood, but it has been shown that CsA
disrupts the transmission of signals from the T
cell receptor to genes that encode multiple
lymphokines needed for activation of resting T
cells such as T helper-inducer and cytotoxic
subsets, while leaving T suppressor cells
unaffected [2, 11]. The SITE study evaluated
373 patients with ocular inﬂammation treated
with CsA in which 52% of them were able to
achieve inﬂammation control and tapering of
systemic steroids was achieved in 36% of
patients at the 1-year time point. About 10.7%
of patients stopped therapy within a year due to
toxicity. About 55 patients discontinued CsA
after 1 year of therapy start due to achieving
remission.
CsA has been effective in patients with
Behcet’s disease, Vogt–Koyanagi–Harada and
sarcoidosis [16]. It can be used as
monotherapy or in conjunction with steroids
or other immunomodulators such as with
mycophenolate mofetil in the setting of
birdshot chorioretinopathy. The most
common side effects noted were hypertension
and renal toxicity, both being dose-dependent.
According to the SITE study, CsA did not show
an increased risk of mortality of cancer [14].
Additional side effects include gingival
hyperplasia, hypertrichosis, normochromic
normocytic anemia, paresthesias, temperature
hypersensitivity, nausea, vomiting,
neurotoxicity manifested by ﬁne hand tremor
and reversible myopathy [2].
It is administered in oral form at starting
doses of 2.5 mg/kg/daily to a maximum dose of
5 mg/kg/day, adjusted to the clinical response
[11]. The topical ophthalmic formulation of
CsA known as Restasis
 (Allergan, Irvine, CA,
USA) is not useful in the therapy of uveitis and
should be used for its approved use of dry eyes
therapy.
Before starting treatment, baseline CBC
with differential, serum creatinine, creatinine
clearance, urinalysis, blood urea nitrogen
(BUN), liver function tests, fasting lipid
proﬁle and blood pressure measurements
should be done. While the dosage is being
adjusted, blood pressure, serum creatinine and
BUN should be checked every 2 weeks and
once the dose has been stabilized then the
testing should be done every 4–6 weeks.
Fasting lipid proﬁles should be monitored at
3-month intervals. Therapy is continued for
2 years once inﬂammation control has been
achieved.
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Tacrolimus is a macrolide antibiotic derivative
from Streptomyces tsukubaensis. It interferes with
the calcineurin phosphatase pathway that
regulates T-cell-based immune responses [1].
Comparison between tacrolimus and CsA
showed comparable efﬁcacy with a lower
incidence of tacrolimus-induced systemic
hypertension and lipid abnormalities [17].
Tacrolimus monotherapy was also shown to
allow oral prednisone tapering to less than
10 mg per day after 14 months in patients
with anterior, intermediate, posterior uveitis,
panuveitis and demonstrated a more favorable
side effect proﬁle [11, 18]. It is dosed 0.05 mg/
kg/day. Possible side effects with tacrolimus
include nephrotoxicity and hypertension with
rare occurrences of headaches, neuropathy and
seizures, all of which are reversible with therapy
cessation [1, 10].
Sirolimus
Sirolimus, also known as rapamycin, is a
macrolide antibiotic derived from Streptomyces
hygroscopicus. It binds to FK Binding Protein (BP)
12 inhibiting the mTOR pathway and activation
of p70 kinase, stopping the cell cycle between
G1 and S phases which prevents the activation
and proliferation of T lymphocytes [1, 11]. It
has also been shown to block the growth factor
proliferation signaling and activation of
hypoxia inducible factor (HIF)-1a.
Sirolimus was shown to be an effective
strategy in reducing inﬂammation [19]. It has
a long history of use in drug-eluting stents in
cardiology and in solid organ transplants. Side
effects include recurrent chest infections,
gastrointestinal and dermatologic problems
[1]. The typical dose is 2 mg daily. A recent
trial evaluating the intravitreal and
subconjunctival administration of sirolimus in
patients with non-infectious uveitis showed
that it is safe and tolerable with no systemic
adverse side effects. It was noted to have
immunomodulatory and steroid-sparing effects
and led to a reduction in vitreous haze and cells
and improvement of visual acuity were noted
[20].
Voclosporin
Voclosporin, also known as luveniq, is a novel
calcineurin inhibitor that affects T helper cells
(TH) 1 and TH17-mediated responses. It was
developed by modifying the functional group of
cyclosporine thereby becoming a more potent
inhibitor and having a more predictable
pharmacokinetic proﬁle [1, 21]. The Lux
Uveitis Multicenter Investigation of a New
Approach to Treatment (LUMINATE) trial
demonstrated superiority to placebo in
reducing vitreous haze and a 50% decrease in
the recurrence rate of inﬂammation at
6 months with tolerable side effects [11, 22].
Voclosporin was dosed orally at 0.4 mg/kg twice
a day. However, the primary endpoint for the
phase 3 clinical trials to show reduction in
vitreous haze at week 12 or at the time of
treatment failure was not achieved and Lux
Biosciences Inc. (NJ, USA) ended its plans to
proceed with the drug development for uveitis.
Alkylating Agents
Alkylating agents interfere with DNA replication
by transferring alkyl groups, cross-linking
nucleic acids, causing abnormal base pairing,
DNA strand breakage and termination of the cell
cycle. It has a cytotoxic effect on rapidly
proliferating cells [1, 2, 11]. Cyclophosphamide
and chlorambucil fall in this category.
Cyclophosphamide (Cytoxan)
It is commonly used in cancer chemotherapy
and in autoimmune disorders. Its action is
24 Ophthalmol Ther (2014) 3:17–36similar to that of nitrogen mustards that cause a
cytotoxic effect to proliferating cells, such as
immunocompetent lymphocytes undergoing
cell division, by alkylating nucleophilic groups
on DNA bases leading to linking of DNA bases,
irregular base pairing and breaks in DNA strands
[1, 11].
Cyclophosphamide has been effective in
treating scleritis caused by underlying systemic
disorders such as granulomatosis with
polyangiitis (GPA), rheumatoid arthritis,
polyarteritis nodosa and relapsing
polychondritis [23–26]. In the SITE cohort
study, 215 patients receiving
cyclophosphamide for ocular inﬂammation
were studied and 76% of them achieved
inﬂammation control at 1 year. A steroid-
sparing effect was noted in 61% of patients.
Similar outcomes in time to control
inﬂammation were noted in those patients
receiving intravenous and oral therapy, but
the patients taking the oral cyclophosphamide
had a higher rate of control. Therapy was
discontinued by 33.5% of patients within a
year due to side effects and in 10.8% for
unknown reasons. Low white blood cell count,
cystitis, and hematuria were the most common
toxicities noted that led to discontinuation of
therapy in 3% of patients during the ﬁrst year.
Opportunistic infections caused therapy
cessation in 3% of patients during the ﬁrst
year, including Pneumocystis carinii pneumonia,
that lead to the death of one patient, managed
using the commonly accepted guidelines, but
who did not take the pneumocystis
prophylaxis. In 9.7% of patients, therapy was
discontinued due to inadequate inﬂammation
control [11, 27]. The SITE study showed no
signiﬁcant increase in overall mortality. The
data suggested a possible increased risk of
cancer mortality with cyclophosphamide use,
but additional data are required since the results
were not conclusive [14].
Oral cyclophosphamide is dosed at 1–3 mg/
kg/day. Intravenous pulsed therapy dosing and
timing is titrated to achieve a white blood cell
count of 3,000–4,500 with an absolute
neutrophil count C1,000. Infusions can occur
every 2–4 weeks and double strength
sulfamethoxazole/trimethoprim (Bactrim DS
;
AR Scientiﬁc, Brampton, Canada) three times a
day is given for phencyclidine (PCP)
prophylaxis. The most toxic potential side
effects occur less frequently with the
intravenous dosing. Monitoring is of utmost
importance and CBC and urinalysis should be
done every 2 weeks. Bladder toxicity from
acrolein, one of the metabolites, and the risk
of bladder cancer is minimized by intermittent
pulsed intravenous (IV) therapy, adequate
hydration, and premedication with
2-mercapto-ethane sulfonate (mesna) [1, 11].
A recent study showed that pulsed IV
cyclophosphamide results in high rate of
sustained complete remission in patients with
recalcitrant and fulminant, vision-threatening
ocular inﬂammatory disease. Its side effect
proﬁle was excellent under the management
of experienced clinicians and its use allowed
tapering and discontinuation of corticosteroids
[28].
Chlorambucil
Chlorambucil is nitrogen mustard that replaces
hydrogen ions with alkyl groups on DNA bases.
It causes intra-strand cross-linking and DNA to
protein cross-linking, disrupting DNA
replication, transcription and function. The
SITE study showed no signiﬁcant increase in
overall mortality in patients treated with
alkylating agents. A non-signiﬁcant increase in
cancer-related mortality was observed.
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studied as cyclophosphamide. It was studied in
Behcet’s disease where high-dose, short-term
therapy was effective in preventing recurrence
after 6–24 months of use [1, 29]. It has also been
used effectively in non-infectious uveitis related
to human leukocyte antigen (HLA)-B27, JIA,
pars planitis, sympathetic ophthalmia, and
Crohn’s disease.
Baseline CBC with differential and liver
function tests are obtained prior to starting
therapy. Close monitoring for side effects and
myelosuppression should be done. Treatment
parameters of white blood cell count of
3,000–4,500 with an absolute neutrophil count
C1,000 should guide therapy. It can be started at
an oral dose of 0.1 mg/kg/day, titrating the dose
to clinical response and tolerance every 3 weeks
with a maximum daily dose of 6–12 mg/day
followed by a progressive reduction of the dose
over the next 3–6 months. Treatment is
continued for 1 year of disease quiescence to
induce durable remission [11]. An alternate
approach is short-term and high-dose therapy
for 3–6 months. The initial dose is of 2 mg a day
for 1 week, followed by an increase of 2 mg/day
each week until inﬂammation is completely
resolved or until the leukocyte count decreases
to below 2,400 cells/ll or platelet count is below
100,000 cells/ll. CBC with differential is done
weekly as the dose is being adjusted. Therapy is
discontinued if bone marrow toxicity occurs
[11]. A combination of the two approaches can
be employed.
Biologic Response Modiﬁers
These agents speciﬁcally target cytokines or
their inﬂammatory signaling pathways. They
have revolutionized the treatment of
inﬂammatory disease and offer novel options
in the management of uveitis.
Etanercept
Etanercept is a soluble, bivalent receptor for
tumor necrosis factor alpha (TNF-a). It
competitively binds TNF-a and TNF-b
inhibiting the immune activities that rely on
these cytokines for signal transduction such as
expression of adhesion molecules responsible
for leukocyte migration and decreased synthesis
of pro-inﬂammatory cytokines and matrix
metalloproteinase (MMP). Etanercept has been
effective in the treatment of arthritis, but its
effect in uveitis is debatable [11, 30]. In a study,
etanercept showed no signiﬁcant efﬁcacy over
placebo in uveitis relapses in patients being
tapered off methotrexate [31]. While other
studies showed some improvement with
etanercept in Behcet’s associated uveitis and
pediatric patients [32]. The SITE study, showed
an increased risk of mortality and cancer-related
mortality in patients taking TNF inhibitors,
including etanercept [14].
It is typically administered via a
subcutaneous injection of 25 mg twice a week
for a period of 2 years. The most common side
effect is pain at the site of injection. Anti-TNF
therapy is not recommended for patients with
active systemic infection. All patients are tested
for latent tuberculosis by tuberculin skin testing
or serum quantiferon testing. Serologic hepatitis
B testing including antibody to hepatitis B core
antigen (anti-HBc) and hepatitis B surface
antigen (HBsAg) was done.
Patients with severe heart failure are excluded
fromusingthistherapy.AbaselineCBCandliver
functiontestsaredonepriortotherapyinitiation
and repeated at 4–6 week intervals. Sustained
remission seems to occur less commonly after
therapy cessation even after a period of 2 years.
Adalimumab
Adalimumab is a fully human immunoglobulin
(Ig) G1 monoclonal anti-TNFa antibody. It is
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arthritis, ankylosing spondylitis, Crohn’s
disease, juvenile idiopathic arthritis,
ankylosing spondylitis and psoriasis.
It has been shown to be effective in
treatment-resistant uveitis, reducing ﬂares of
uveitis in the pediatric populations and in
patients with juvenile idiopathic arthritis, and
in patients with spondyloarthropathy-
associated uveitis [33–37]. Overall malignancy
and mortality rates were comparable to those in
the general population as shown by Burmester
et al. [38]. Further studies are needed to assess
the long-term safety of adalimumab in treating
uveitis and if it follows the similar long-term
effects of etanercept and inﬂiximab.
It is administered via pre-packaged
subcutaneous injection in doses of 40 mg and it
istypicallygivenat2-weekintervals.However,the
interval can be decreased to 1 week if additional
control is necessary. It can be used inconjunction
with other immunomodulator agents such as
methotrexate and mycophenolate mofetil in
order to achieve remission. The common side
effects include pain at the site of injection, upper
respiratory, sinus and urinary tract infections,
gastrointestinal discomfort, elevated cholesterol
and high blood pressure. Baseline CBC and liver
function tests are done prior to starting therapy
and repeated at 3-month intervals while the
patient is taking the medication. Therapy
duration should be 2 years in order to be able to
achieve sustainable remission.
Inﬂiximab
InﬂiximabisachimericIgGmonoclonalantibody
directed at soluble and transmembrane forms of
TNF-a. It has been used in treating autoimmune
disorders such as psoriasis, rheumatoid arthritis,
Crohn’s disease. It is only effective against TNF-a.
Studies have revealed efﬁcacy in treating ocular
complications of Behcet’s disease not controlled
withotheragentsandsuccesshasalsobeennoted
in treating refractory uveitis in patients with
juvenile idiopathic arthritis and ankylosing
spondylitis [39–41].
TNF-a is involved in host defense against
infections with pathogens such as
Mycobacterium, Aspergillus, Histoplasma,
Toxoplasma and Candida and could make
patients susceptible to reactivation with
tuberculosis [42]. Inﬂiximab has been
associated anaphylactic reactions,
demyelinating disease and heart failure and
should be used with caution in patients with a
known past medical history that may be affected
by potential side effects [43]. The SITE cohort
showed inﬂiximab group to have a greater risk of
cancer and overall mortality; however, it is
proposed that TNF inhibitors do not initiate
cancer but exacerbate pre-existing malignancies
that are undetected [11, 14]. A study evaluating
theeffects of inﬂiximabinpatientswithBehcet’s
disease uveoretinitis showed that it was well
tolerated with no serious adverse effects
occurring in about half of the patients. At the
1-year endpoint, the uveoretinitis had improved
in92% of patients. No ﬂare-upswere seen during
the 1 year period in 44% of patients and
improvement in visual acuity was noted [44].
Inﬂiximab is administered as an intravenous
infusion at 5 mg/kg at week 0 and 2 as loading
doses followed by infusions at 4-week intervals.
For refractory cases, the doses can be as high as
10 mg/kg. The dosing can be increased or
tapered and the dosing intervals can be
adjusted based on clinical response and state of
inﬂammation. Based on the authors experience
within the Massachusetts Eye Research and
Surgery Institution (MERSI), inﬂiximab is the
most efﬁcacious amongst the targeting
antibodies for the treatment of ocular
inﬂammatory disease, but its use may be
limited by the need for monthly infusions.
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repeated annually during the duration of
therapy, and a baseline CBC and LFT is done
and repeated at 4- to 6-week intervals [1].
Daclizumab
Daclizumab is a humanized monoclonal
antibody against the interleukin (IL)-2 receptor
of activated lymphocytes. It binds to the cluster
differentiation (CD) 25 portion of the IL-2
receptor; thereby, inhibiting the IL-2 mediated
cytokine response.
It affects the T-lymphocyte response and
does not have an impact on the humoral
immune pathways.
It showed effectiveness in treating childhood
uveitis, non-infectious intermediate and
posterior uveitis and refractory inﬂammatory
disease. Efﬁcacy was also demonstrated in
treating birdshot retinochoroidopathy [11, 45–
49]. The dose is 1–4 mg/kg given intravenously
every 14 days. It is generally well tolerated with
side effects ranging from headaches, nausea,
lymphadenopathy and skin reactions.
Daclizumab was not examined in the SITE
cohort study; however, studies done on patients
receiving it for transplants did not show an
increased risk of malignancy or mortality [50].
Unfortunately, daclizumab was withdrawn from
the market in January 2010 due to its projected
revenue when compared to alternative
medications in the renal transplant ﬁeld [11].
Rituximab
Rituximab is a murine/human chimeric
monoclonal IgG antibody against the CD20
antigen in B lymphocytes, thereby serving as a
strong immune suppressant of the humoral arm
of the immune system. The CD 20 marker is
essential in B lymphocyte activation and
differentiation [1]. It also inhibits T-cell
activation through a reduction of antigen
presentation by B cells and by inducing lysis
of peripheral B lymphocytes. It has been
employed in the therapy of lymphoma,
leukemia, multiple myeloma, rheumatoid
arthritis and uveitis [1]. Rituximab has been
useful in treating chronic anterior uveitis
refractive to steroids and other steroid agents
[51], inducing remission in a patient with
relapsing necrotizing scleritis associated with
granulomatosis with polyangiitis (Wegener’s)
(GPA) [52], and inducing remission of retinal
vasculitis in a patient with Behcet’s disease [53].
In MERSI, good results have been observed in
inducing remission with rituximab in patients
with refractory uveitis and treatment-resistant
ocular cicatricial pemphigoid [1].
Rituximab is administered as an intravenous
infusion, 375 mg/m
2, every week for 4 weeks.
Possible side effects include ﬂu-like symptoms,
headache, nausea, fatigue and rash. A baseline
CBC should be obtained and monitored during
therapy for evidence of neutropenia that could
render patients vulnerable to infection.
Rituximab can also be given in conjunction
with intravenous immunoglobulin (IVIG) in
patients with recalcitrant ocular cicatricial
pemphigoid. It is infused at 375 mg/m
2, once
weekly for 8 weeks and then infused monthly
for 4 months, for a total of 6 months of therapy
[54]. IVIG is infused 1 month prior to starting
rituximab therapy, and then monthly until
B-cell levels decrease to within normal limits.
Afterwards, IVIG is given at 6, 8, 10, 12, 14, and
16 weeks. CBC and peripheral blood B-cell
levels (CD20? cells) testing via ﬂow cytometry
are done prior to every infusion [11].
Intravenous Immunoglobulin
Intravenous immunoglobulin (IVIG) treats
autoimmune disease without suppressing the
immune system.
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interaction with Fc receptors or cross-linking of
antibodies [55]. It is an effective therapy in the
situation of refractory inﬂammation or in
patients with medication intolerance [56–58].
It is administered via intravenous infusion at
2 g/kg spaced over a 2- to 3-day period. Side
effects include aseptic meningitis that usually
occurs within the 24 h of infusion completion
and may last for about 5 days. The infusions can
be administered over an 8-h period and can be
given on an every other day basis to minimize
this effect. The patient may also be pre-
medicated and may be given post-infusion
pain control [59]. Additional serious reactions
include acute renal failure, thromboembolic
events and anaphylaxis. IVIG can be used in
conjunction to rituximab in patients with
recalcitrant ocular cicatricial pemphigoid [54].
Interferon
Interferons (IFNS) are a group of cytokines
produced by diverse cell populations with
immunomodulatory, antiproliferative and
antiviral qualities. Type 1 IFNs are the most
clinically important in the setting of ocular
inﬂammation and include IFN-b and IFNa.
These two subtypes increase the expression of
the major histocompatibility class (MHC) 1
surface molecules and activate NK cells and
macrophages [52]. IFN-a2a and IFN-a2b are used
in the therapy of hepatitis C and IFN-b1a and
IFN-b1b are employed in multiple sclerosis [60].
It has been used in patients with ocular
manifestations of Behcet’s disease since 1994
and was effective in causing a response rate of
92% with signiﬁcant improvement in ocular
inﬂammation and visual acuity [61, 62].
Patients with multiple sclerosis-associated
uveitis were treated with IFN-b1a in case series
and experienced improvements in ocular
inﬂammation, macular edema and visual
acuity [63].
Side effects included fatigue, ﬂu-like
syndromes, mood changes such as depression
and medication-induced SLE. IFNa2a is given at
dose of 3–6 million IU daily to three times a
week [63]. Liver function tests, CBC and thyroid
function tests are done prior to therapy
initiation and then at 4- to 6-week intervals.
Treatment is continued with a goal of achieving
inﬂammation control for 2 years prior to
stopping therapy.
Tocilizumab
Tocilizumab is a humanized antibody to IL-6
which is an important cytokine involved in B
and T cell activation and differentiation. It is
currently approved for treatment of patients
with moderate to severe rheumatoid arthritis or
patients who have not had a favorable response
to TNF-a agents [64, 65]. Currently, there are
studies evaluating its efﬁcacy in treating ocular
inﬂammation.
It is administered intravenously at 4–8 mg/
kg at 4-week intervals. Potential side effects
include elevated liver enzymes,
thrombocytopenia, neutropenia, increased
lipid values and therefore CBC and liver
function tests should be done at 4- to 6-week
intervals [11, 66]. Since Tocilizumab does not
affect granulomatous inﬂammation,
reactivation of latent tuberculosis does not
pose a risk to patients.
Anakinra
Anakinra is an IL-1 receptor antagonist, IgG
monoclonal antibody currently approved for
rheumatoid arthritis [67]. IL-1 is a cytokine
involved in the stimulation of inﬂammation
and recruitment of inﬂammatory cells to a
particular tissue [68]. A multi-center trial
showed efﬁcacy of Anakinra as ﬁrst-line
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subcutaneous injection 100 mg daily.
Pregnancy and Uveitis Management
Appropriate contraception should be used
during the use of immunosuppressive therapy.
Prednisone seems to be the most widely used
systemic anti-inﬂammatory agent, safest and
best tolerated during pregnancy. Its use does
not appear to adversely affect fertility. Animal
studies noted developmental defects with
topical corticosteroids such as cleft lip and
palate. No studies have been conducted on the
nursing infant or if there are detectable levels in
breast milk. However, human studies of
corticosteroid-treated pregnant patients with
asthma receiving a mean dose of 8 mg of
prednisone daily did not show an increase in
the incidence of birth defects when compared
to the normal population [2, 10, 70, 71]. The
American Association of Pediatrics has declared
prednisone and prednisolone safe and
compatible with breastfeeding.
Alkylating agents are cytotoxic, teratogenic
and can cause sterility and should be avoided
during pregnancy. Effective contraception is
mandatory and patients should consider sperm
banking or ova cryopreservation prior to the
initiation of therapy. Attempts at conception
should be delayed until 3 months after stopping
therapy. Cyclophosphamide has been shown to
cause skeletal, palate and limb malformations in
animal studies while chlorambucil can cause
cardiac and urogenital abnormalities.
Breastfeeding is contraindicated [2].
Azathioprine has been studied in pregnant
renal transplant patients receiving azathioprine
and prednisone and in pregnant patients with
inﬂammatory bowel disease treated with
azathioprine or 6-mercaptopurine. These
studies showed no increase in pregnancy
complications or congenital malformations.
Risks including lower gestational age, birth
weight and prematurity have been reported [2,
10, 72, 73]. The fetal liver does not have the
enzyme to convert azathioprine to its active
form and may be protected from its effects. It
may be used during pregnancy in situations of
severe sight-threatening uveitis at daily dose
not exceeding 2 mg/kg/day and breastfeeding is
not recommended.
Methotrexate is also teratogenic and at
elevated doses may have abortifacient
properties and is contraindicated during
pregnancy. Congenital anomalies include
neural tube defects, limb, palate and growth
retardation and cranial ossiﬁcation [2, 10].
Although methotrexate has not been shown to
affect female fertility, there is a risk of sperm
mutation in treated male patients. Therefore, it
is recommended the methotrexate should be
discontinued 4 months prior to conception.
Breastfeeding is also contraindicated [2, 10].
Mycophenolate mofetil has been shown to
cross the placenta, but no data are available on
teratogenic effects. It is contraindicated in
pregnancy and during breast feeding. Due to
its long half-life and hepatic circulation, it
should be discontinued 6 weeks prior to
conception.
Tacrolimus and cyclosporine cross the
placenta. A recent study reviewing cyclosporine
therapy during pregnancy concluded that the
prevalence of major malformation in this group
didnotvarysubstantiallywiththatofthegeneral
population [2, 74]. Both agents may be
maintained in pregnancy at the lowest effective
dose. Breast feeding is not recommended.
The use of biologic response modiﬁers such
as etanercept, adalimumab and inﬂiximab is
growing, but there is limited experience on
their use during pregnancy and breastfeeding.
As a result, these agents should be stopped once
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use of rituximab in pregnant patients with
B-cell malignancies and autoimmune diseases
have not revealed teratogenic or fetotoxic
effects suggesting that this therapy may offer
an alternative during pregnancy [2, 75].
Intravenous immunoglobulin has been
safely used to prevent recurrent pregnancy loss
in patients undergoing therapy for GPA and as
preventive therapy for congenital heart block
[2, 76, 77]. It has a safe side effect proﬁle but the
limiting factors include cost, long infusions
during a 3-day period each month. Its use has
allowed patients to conceive and carry their
pregnancy to term while also controlling their
uveitis. It is secreted in breast milk and may
transfer protective antibodies to the neonate
[2].
The use of IFN-a during pregnancy has been
documented in treating patients with hepatitis
C, chronic inﬂammatory demyelinating
polyneuropathy and essential
thrombocythemia [78–80].
Emerging Therapies
Recent developments in uveitis therapies have
shifted focus to targeting inﬂammatory
cytokines, T-cell activation, T-cell migration,
downstream pathways by using small molecule
inhibitors. Developments of antibodies
generated against inﬂammatory cytokines
involved in uveitis and other autoimmune
diseases such as IL-17, IL-23, IL-22 and IL-6
have been under investigation and offer novel
strategies. Small molecule inhibitors of Janus
kinases and protein kinases may offer strategies
to modulate the intracellular downstream
signaling. Tofacitinib is FDA approved for
rheumatoid arthritis and sotrastaurin currently
studied in phase 2 trials in patients with
macular edema associated with uveitis offer
examples of this approach, respectively. Small
interfering RNA (siRNA) and microRNA
technology can also be utilized to inhibit the
expression of inﬂammatory cytokines [81].
Improved local drug delivery methods are
also being advanced. Lee et al. [82]
demonstrated the effectiveness of topical
tacrolimus ointment in controlling refractory
inﬂammatory ocular surface disease, such as
scleritis and Mooren ulcer, and reducing
inﬂammation recurrence and reliance on
steroid use. For the intravitreal route, trials of
micro-particle injectables are being conducted.
These can be in the form of drug-eluting micro-
particles with sizes of 1–10 lm, suspended in a
liquid carrier or microspheres with drug–
polymer associations dispersed within a
polymeric matrix [81]. For example,
Tethadur
TM (pSivida, MA, USA) is a porous
silicone micro-particle designed to have
sustained release of proteins, peptides,
chemical molecules and therapeutic
antibodies. Intravitreal injections of a viscous
gel or liquid can be formulated to release
monoclonal antibodies and small peptides,
proteins and molecules as demonstrated by
the Verisome
 system (Icon Bioscience, Inc.
CA, USA) [81, 83]
CONCLUSION
The advances in the understanding of the
immune system and the mechanisms behind
autoimmune disease and ocular
inﬂammatory disease have permitted new
insights and developments of diverse
therapies. Further work is needed to further
clarify long-term effects in the case of the
biologic response modiﬁers and to assess
w h i c hm e d i c a t i o ni sb e s ti n d i c a t e df o ra
particular disease.
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scenario and therapy must be individualized.
Long-term therapy may be needed with
antimetabolites and T-cell inhibitors while
therapy with alkylating agents may result in
long-term, drug-free remission [10]. The
strategy to use combination therapy gives the
opportunity to modulate the various arms of
the immune system leading to enhanced
immunosuppression and limiting dose toxicity
[10]. The understanding is that chronic
corticosteroid therapy is almost never curative
and carries signiﬁcant side effects, while
immunomodulatory therapy (IMT) when used
appropriately as a way to induce steroid-free
remission carries less risk of causing long-term
complications. IMT provides greater potential
of altering the immune system to induce
remission and allow the patient to be cured of
their ocular inﬂammatory disease and be able to
discontinue medications without any further
relapses [84].
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